Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Onconase cytotoxic RNase enzyme data

ACEL (Bloomfield, N.J.) reported Phase I/II findings in 32 evaluable patients, eight of whom

Read the full 149 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE